• OUTLOOK ARENA
  • VIEWS ON NEWS
  • JULY 24, 2000

Nicholas Piramal: New products make up for anti–infective decline

Despite a 12% degrowth in anti–infectives in the first quarter, Nicholas Piramal has managed to report a 32% growth in bottomline. This was primarily on the back of new introductions such Rejoint (a nutraceutical consumed by arthirtis patients) and Haemaccel and Omnatax which were taken over from Hoechst.

(Rs m)1QFY001QFY01Change
Sales 1,121 1,325 18.2%
Other Income 14 12 -12.5%
Expenditure 938 1,098 17.1%
Operating Profit (EBDIT) 184 227 23.6%
Operating Profit Margin (%)16.4%17.1% 
Interest (net) 43 40  
Depreciation 25 33 32.3%
Profit before Tax13016628.0%
Other Adjustments   
Tax 15 14 -6.7%
Profit after Tax/(Loss) 115 152 32.5%
Net profit margin (%)10.2%11.5% 
No. of Shares (m) (eoy)27.734.9 
Diluted no. of shares (m)34.934.9 
Diluted Earnings per share*13.217.4 
*(annualised)   

The company has launched new products including Bulaquin (an anti–malarial), Alginic Acid (a gastrointestinal), atorvastatin (a cardiovascular) and cefixime (anti–infective). These are expected to contribute to the turnover in the subsequent quarters.

The stock quotes at a price of Rs 336 which implies an earning multple of 19.3 times on the annualised earnings for FY2001.

Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

Equitymaster Agora Research Private Limited (Research Analyst)
103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407